Jayashree Sinha is a Rheumatology/Immunology physician. OpenAlex indexes 8 publications with 526 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1600 W 21st St
Suite B
Clovis, NM 881014084
Telephone
575-935-5051Registry record last updated 10 Jun 2008.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202516 payments
- ANI Pharmaceuticals, Inc.Program year202514 payments
- Mallinckrodt Hospital Products Inc.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
93.4%Interleukin-6 Receptor Antagonist75.5%Tocilizumab100%Kevzara0%Actemra Actpen0%Part D + Part B<11 patientsSelective T Cell Costimulation Modulator15.1%Abatacept98%Orencia Clickject1%Orencia0%Part D + Part B<11 patients+ 6 more classes in this area
Musculoskeletal
2.4%RANK Ligand Inhibitor2.1%Denosumab100%Part B, office-administered≥11 patientsCyclooxygenase Inhibitor0.3%Ketorolac tromethamine100%Part B, office-administered≥25 patientsDermatology
1.4%Corticosteroid1.4%Triamcinolone acetonide89%Methylprednisolone11%Part D + Part B≥82 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Co‐Stimulatory Blockade in the Treatment of Murine Systemic Lupus Erythematosus (SLE)
Annals of the New York Academy of Sciences
2003 - The effect of anti‐CD40 ligand antibody on B cells in human systemic lupus erythematosus
Arthritis & Rheumatism
2002 - Mechanism of Action of Combined Short-Term CTLA4Ig and Anti-CD40 Ligand in Murine Systemic Lupus Erythematosus
The Journal of Immunology
2002
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”